Ann: CEO 2012 AGM Presentation , page-10

Thanks for working the figures Maddoc

For the sometimes numerically challenged such as myself it's very helpful. Blue sky of course, but it gives a feel for the scope of this as an earner.

Just one thing though: you are talking about the SP, surely we can expect this to become a nice little dividend payer over time? Difficult to quantify and they may well use revenue to fund research for other applications, and FDA approval for them but still, I would expect some dividends over time.

I am slightly frazzled over the patient recruitment problems but this has always been more difficult than appeared at first.

BTW last weekend's AFR had an expert in equities from the US saying the next big thing after the resource boom for Australia will be biotechs. We already know that and are in at the ground floor on this.

GLTA